Literature DB >> 27069109

Coronary Artery Bypass Grafting Versus Percutaneous Coronary Intervention in Patients With Left Ventricular Systolic Dysfunction: A Meta-Analysis.

Dongfeng Zhang1, Shuzheng Lyu2, Xiantao Song2, Fei Yuan1, Feng Xu1, Min Zhang1, Mingduo Zhang1.   

Abstract

The optimal method of coronary revascularization for patients with coronary artery disease (CAD) and left ventricular (LV) systolic dysfunction is unclear. The purpose of this meta-analysis was to compare coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI) in these patients. Two investigators independently searched PubMed, EMBASE, and the Cochrane Controlled Trials Register databases for relevant studies. Four prospective and 5 retrospective studies, published before March 2015, involving 6082 patients were included. Compared with PCI, CABG was significantly associated with lower long-term death (odds ratio [OR]: 0.82, 95% confidence interval [CI]: 0.70-0.96, P = .01, I 2 = 0%), myocardial infarction (OR: 0.58, 95% CI: 0.36-0.95, P = .03, I 2 = 44%), and repeat revascularization (OR: 0.17, 95% CI: 0.14-0.22, P < .001, I 2 = 32%). The short-term death rate was comparable between CABG and PCI (OR: 2.09, 95% CI: 0.80-5.45, P = .13, I 2 = 9%). Coronary artery bypass grafting has long-term benefits compared with PCI in patients with CAD and LV dysfunction.
© The Author(s) 2016.

Entities:  

Keywords:  coronary artery bypass grafting; coronary artery disease; left ventricular systolic dysfunction; percutaneous coronary intervention

Mesh:

Year:  2016        PMID: 27069109     DOI: 10.1177/0003319716639197

Source DB:  PubMed          Journal:  Angiology        ISSN: 0003-3197            Impact factor:   3.619


  1 in total

1.  Adverse Cardiovascular Outcomes associated with Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention with Everolimus Eluting Stents: A Meta-Analysis.

Authors:  Pravesh Kumar Bundhun; Manish Pursun; Abhishek Rishikesh Teeluck; Akash Bhurtu; Mohammad Zafooruddin Sani Soogund; Wei-Qiang Huang
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.